Annual CFO
-$4.29 M
+$318.40 K+6.90%
December 31, 2023
Summary
- As of February 26, 2025, LIXT annual cash flow from operations is -$4.29 million, with the most recent change of +$318.40 thousand (+6.90%) on December 31, 2023.
- During the last 3 years, LIXT annual CFO has fallen by -$2.16 million (-101.43%).
- LIXT annual CFO is now -12949.54% below its all-time high of -$32.90 thousand, reached on December 31, 2005.
Performance
LIXT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$957.60 K
-$138.60 K-16.92%
September 30, 2024
Summary
- As of February 26, 2025, LIXT quarterly cash flow from operations is -$957.60 thousand, with the most recent change of -$138.60 thousand (-16.92%) on September 30, 2024.
- Over the past year, LIXT quarterly CFO has stayed the same.
- LIXT quarterly CFO is now -3260.00% below its all-time high of -$28.50 thousand, reached on June 30, 2006.
Performance
LIXT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$3.47 M
-$13.20 K-0.38%
September 30, 2024
Summary
- As of February 26, 2025, LIXT TTM cash flow from operations is -$3.47 million, with the most recent change of -$13.20 thousand (-0.38%) on September 30, 2024.
- Over the past year, LIXT TTM CFO has stayed the same.
- LIXT TTM CFO is now -5251.70% below its all-time high of -$64.80 thousand, reached on March 31, 2006.
Performance
LIXT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
LIXT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.9% | 0.0% | 0.0% |
| 3 y3 years | -101.4% | +18.5% | +28.2% |
| 5 y5 years | -184.1% | +18.5% | +28.2% |
LIXT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -3.6% | +6.9% | -21.3% | +24.7% | -0.4% | +28.5% |
| 5 y | 5-year | -156.4% | +6.9% | -170.1% | +24.7% | -107.2% | +28.5% |
| alltime | all time | <-9999.0% | +6.9% | -3260.0% | +24.7% | -5251.7% | +28.5% |
Lixte Biotechnology Holdings Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$957.60 K(+16.9%) | -$3.47 M(+0.4%) |
| Jun 2024 | - | -$819.00 K(+3.8%) | -$3.45 M(-9.4%) |
| Mar 2024 | - | -$789.20 K(-12.5%) | -$3.81 M(-11.2%) |
| Dec 2023 | -$4.29 M(-6.9%) | -$902.10 K(-4.5%) | -$4.29 M(-6.7%) |
| Sep 2023 | - | -$944.40 K(-19.7%) | -$4.60 M(-4.8%) |
| Jun 2023 | - | -$1.18 M(-7.6%) | -$4.83 M(-0.4%) |
| Mar 2023 | - | -$1.27 M(+5.2%) | -$4.85 M(+5.1%) |
| Dec 2022 | -$4.61 M(+11.3%) | -$1.21 M(+2.9%) | -$4.61 M(+1.4%) |
| Sep 2022 | - | -$1.17 M(-1.7%) | -$4.55 M(+5.7%) |
| Jun 2022 | - | -$1.19 M(+15.4%) | -$4.30 M(+3.7%) |
| Mar 2022 | - | -$1.04 M(-9.7%) | -$4.15 M(+0.2%) |
| Dec 2021 | -$4.14 M(+94.4%) | -$1.15 M(+23.6%) | -$4.14 M(+10.9%) |
| Sep 2021 | - | -$927.90 K(-10.9%) | -$3.73 M(+8.9%) |
| Jun 2021 | - | -$1.04 M(+1.5%) | -$3.43 M(+25.0%) |
| Mar 2021 | - | -$1.03 M(+38.9%) | -$2.74 M(+28.7%) |
| Dec 2020 | -$2.13 M(+27.3%) | -$739.00 K(+18.5%) | -$2.13 M(+20.4%) |
| Sep 2020 | - | -$623.70 K(+75.9%) | -$1.77 M(+2.1%) |
| Jun 2020 | - | -$354.60 K(-14.3%) | -$1.73 M(+1.5%) |
| Mar 2020 | - | -$414.00 K(+9.7%) | -$1.71 M(+2.1%) |
| Dec 2019 | -$1.67 M(+10.8%) | -$377.50 K(-35.8%) | -$1.67 M(-10.6%) |
| Sep 2019 | - | -$587.60 K(+78.3%) | -$1.87 M(+29.2%) |
| Jun 2019 | - | -$329.60 K(-13.1%) | -$1.45 M(+4.1%) |
| Mar 2019 | - | -$379.40 K(-34.2%) | -$1.39 M(-7.8%) |
| Dec 2018 | -$1.51 M(+7.0%) | -$576.60 K(+250.3%) | -$1.51 M(+24.0%) |
| Sep 2018 | - | -$164.60 K(-39.5%) | -$1.22 M(-19.5%) |
| Jun 2018 | - | -$272.00 K(-45.3%) | -$1.51 M(-4.2%) |
| Mar 2018 | - | -$497.70 K(+75.1%) | -$1.58 M(+11.9%) |
| Dec 2017 | -$1.41 M(-15.8%) | -$284.30 K(-38.2%) | -$1.41 M(-11.6%) |
| Sep 2017 | - | -$460.40 K(+36.1%) | -$1.60 M(-1.2%) |
| Jun 2017 | - | -$338.40 K(+2.9%) | -$1.62 M(-3.8%) |
| Mar 2017 | - | -$329.00 K(-30.0%) | -$1.68 M(+0.2%) |
| Dec 2016 | -$1.68 M(-23.1%) | -$469.80 K(-2.1%) | -$1.68 M(-7.8%) |
| Sep 2016 | - | -$480.10 K(+19.5%) | -$1.82 M(-1.6%) |
| Jun 2016 | - | -$401.60 K(+23.2%) | -$1.85 M(-6.1%) |
| Mar 2016 | - | -$325.90 K(-46.8%) | -$1.97 M(-9.8%) |
| Dec 2015 | -$2.18 M | -$612.30 K(+20.3%) | -$2.18 M(-1.5%) |
| Sep 2015 | - | -$508.90 K(-2.4%) | -$2.21 M(+8.4%) |
| Jun 2015 | - | -$521.30 K(-3.2%) | -$2.04 M(+12.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$538.60 K(-16.4%) | -$1.81 M(+10.9%) |
| Dec 2014 | -$1.64 M(+38.6%) | -$644.40 K(+90.8%) | -$1.64 M(+25.1%) |
| Sep 2014 | - | -$337.80 K(+15.0%) | -$1.31 M(+4.3%) |
| Jun 2014 | - | -$293.70 K(-18.3%) | -$1.25 M(-0.4%) |
| Mar 2014 | - | -$359.60 K(+13.8%) | -$1.26 M(+6.7%) |
| Dec 2013 | -$1.18 M(-2.1%) | -$316.00 K(+11.1%) | -$1.18 M(+8.3%) |
| Sep 2013 | - | -$284.40 K(-4.9%) | -$1.09 M(-1.0%) |
| Jun 2013 | - | -$299.20 K(+6.7%) | -$1.10 M(-11.0%) |
| Mar 2013 | - | -$280.50 K(+24.3%) | -$1.24 M(+2.6%) |
| Dec 2012 | -$1.21 M(-11.3%) | -$225.70 K(-23.7%) | -$1.21 M(-22.0%) |
| Sep 2012 | - | -$295.90 K(-32.0%) | -$1.55 M(-6.5%) |
| Jun 2012 | - | -$435.30 K(+74.8%) | -$1.65 M(+7.9%) |
| Mar 2012 | - | -$249.00 K(-56.0%) | -$1.53 M(+12.7%) |
| Dec 2011 | -$1.36 M(+45.2%) | -$565.60 K(+39.9%) | -$1.36 M(+36.3%) |
| Sep 2011 | - | -$404.20 K(+28.9%) | -$997.80 K(+25.2%) |
| Jun 2011 | - | -$313.60 K(+311.5%) | -$796.90 K(+4.8%) |
| Mar 2011 | - | -$76.20 K(-62.6%) | -$760.20 K(-18.8%) |
| Dec 2010 | -$936.40 K(+46.7%) | -$203.80 K(+0.2%) | -$936.30 K(+7.1%) |
| Sep 2010 | - | -$203.30 K(-26.6%) | -$873.90 K(+5.8%) |
| Jun 2010 | - | -$276.90 K(+9.8%) | -$825.90 K(+20.6%) |
| Mar 2010 | - | -$252.30 K(+78.4%) | -$684.90 K(+7.3%) |
| Dec 2009 | -$638.40 K(+6.8%) | -$141.40 K(-9.0%) | -$638.40 K(+4.6%) |
| Sep 2009 | - | -$155.30 K(+14.3%) | -$610.40 K(-3.6%) |
| Jun 2009 | - | -$135.90 K(-34.0%) | -$633.30 K(+1.4%) |
| Mar 2009 | - | -$205.80 K(+81.5%) | -$624.60 K(+4.5%) |
| Dec 2008 | -$597.70 K(-15.0%) | -$113.40 K(-36.4%) | -$597.70 K(-5.4%) |
| Sep 2008 | - | -$178.20 K(+40.1%) | -$631.90 K(+20.5%) |
| Jun 2008 | - | -$127.20 K(-28.9%) | -$524.30 K(-29.1%) |
| Mar 2008 | - | -$178.90 K(+21.2%) | -$739.00 K(+5.1%) |
| Dec 2007 | -$702.90 K(+58.5%) | -$147.60 K(+109.1%) | -$702.90 K(+13.8%) |
| Sep 2007 | - | -$70.60 K(-79.4%) | -$617.60 K(-26.0%) |
| Jun 2007 | - | -$341.90 K(+139.4%) | -$834.80 K(+60.1%) |
| Mar 2007 | - | -$142.80 K(+129.2%) | -$521.40 K(+17.6%) |
| Dec 2006 | -$443.50 K(+1248.0%) | -$62.30 K(-78.4%) | -$443.40 K(+16.3%) |
| Sep 2006 | - | -$287.80 K(+909.8%) | -$381.10 K(+308.5%) |
| Jun 2006 | - | -$28.50 K(-56.0%) | -$93.30 K(+44.0%) |
| Mar 2006 | - | -$64.80 K | -$64.80 K |
| Dec 2005 | -$32.90 K | - | - |
FAQ
- What is Lixte Biotechnology Holdings annual cash flow from operations?
- What is the all time high annual CFO for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings annual CFO year-on-year change?
- What is Lixte Biotechnology Holdings quarterly cash flow from operations?
- What is the all time high quarterly CFO for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings quarterly CFO year-on-year change?
- What is Lixte Biotechnology Holdings TTM cash flow from operations?
- What is the all time high TTM CFO for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings TTM CFO year-on-year change?
What is Lixte Biotechnology Holdings annual cash flow from operations?
The current annual CFO of LIXT is -$4.29 M
What is the all time high annual CFO for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high annual cash flow from operations is -$32.90 K
What is Lixte Biotechnology Holdings annual CFO year-on-year change?
Over the past year, LIXT annual cash flow from operations has changed by +$318.40 K (+6.90%)
What is Lixte Biotechnology Holdings quarterly cash flow from operations?
The current quarterly CFO of LIXT is -$957.60 K
What is the all time high quarterly CFO for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high quarterly cash flow from operations is -$28.50 K
What is Lixte Biotechnology Holdings quarterly CFO year-on-year change?
Over the past year, LIXT quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Lixte Biotechnology Holdings TTM cash flow from operations?
The current TTM CFO of LIXT is -$3.47 M
What is the all time high TTM CFO for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high TTM cash flow from operations is -$64.80 K
What is Lixte Biotechnology Holdings TTM CFO year-on-year change?
Over the past year, LIXT TTM cash flow from operations has changed by $0.00 (0.00%)